RecruitingPhase 3NCT07014826

A Trial of HRS-5965 Capsule in Primary IgA Nephropathy

Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of HRS-5965 Capsule in Primary IgA Nephropathy

Sponsor

Chengdu Suncadia Medicine Co., Ltd.

Enrollment

378 participants

Start Date

Jun 4, 2025

Study Type

INTERVENTIONAL

Conditions

Primary IgA Nephropathy

Summary

This multicenter, randomized, double-blind, parallel, placebo-controlled study is being conducted to evaluate the efficacy, and safety of HRS-5965 capsule for primary IgA nephropathy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HRS-5965 and a drug called Placebo for people with primary iga nephropathy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.